ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On January4, 2017, Abbott Laboratories completed the acquisition
of St. Jude Medical,Inc. Beginning with the first quarter of
2017, Abbotts cardiovascular and neuromodulation (ACN) business
will include its historical Vascular Products segment and the
businesses of St. Jude Medical,Inc. ACNs sales results will be
reported in the following categories:
Rhythm Management and Heart Failure: This
product category will include traditional pacemakers and
implantable cardioverter-defibrillators (ICDs), bi-ventricular
cardiac resynchronization therapy pacemakers and ICDs, atrial
fibrillation products, ventricular assist devices, and the
CardioMEMS HF system.
Cardiovascular and Structural Heart: This
product category will include a broad line of coronary,
endovascular, and vessel closure devices, diagnostic coronary
imaging technology, percutaneous heart pumps, heart valve
replacement and repair devices, patent foramen ovale closure
devices, and left atrial appendage closure products.
Neuromodulation: This product category will
include spinal cord stimulation products, dorsal root ganglion
stimulation products, and deep brain stimulation products.
Please see Exhibit99.1 for comparable revenue in each product
category for each quarter of 2016 and for the full year.
The information contained in this Current Report on Form8-K and
the Exhibithereto shall not be deemed to be filed for the
purposes of Section18 of the Securities Exchange Act of 1934 (the
Exchange Act) or otherwise subject to the liabilities of that
section, nor shall it be incorporated by reference into a filing
under the Securities Act of 1933, or the Exchange Act.
Item 9.01 Financial Statements and
Exhibits
|
ExhibitNo. |
|
Exhibit |
|
|
99.1 |
Comparable Sales by Product (furnished to Item 2.02). |
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ABBOTT LABORATORIES |
||
|
|
|
|
|
Date:January25, 2017 |
By: |
|
|
/s/ Brian B. Yoor |
||
|
Brian B. Yoor, Senior Vice President, Finance and Chief |
EXHIBITINDEX
|
ExhibitNo. |
|
Exhibit |
|
99.1 |
Comparable Sales by Product (furnished |
About ABBOTT LABORATORIES (NYSE:ABT)
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products. ABBOTT LABORATORIES (NYSE:ABT) Recent Trading Information
ABBOTT LABORATORIES (NYSE:ABT) closed its last trading session down -0.03 at 40.31 with 7,773,693 shares trading hands.
